We report a unique case of breast implant-associated anaplastic large cell lymphoma (BI-ALCL) with progressive systemic dissemination with extensive bone and bone marrow involvement. This case expands the clinical and pathologic spectrum of BI-ALCL and shows that although typically localized, BI-ALCL may present with disseminated disease with multiorgan involvement including bone and bone marrow. Disseminated BI-ALCL should be considered in the differential diagnosis of systemic ALCL. Unlike patients with localized disease, patients with disseminated BI-ALCL may benefit from systemic chemotherapy or immunotherapy.
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Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a recently recognized T-cell lymphoma 1 that arises around breast implants and is often delimited by a fibrous capsule. Most cases present with effusion confined to the capsule, while a subset of patients present with a tumor mass that infiltrates the capsule and beyond extending into surrounding soft tissues or breast parenchyma. 2 The majority of BI-ALCL remains localized to the breast and is cured with complete excision. However, approximately 20% of patients present with lymphadenopathy and a lesser percentage with infiltration into the chest wall and regional extension, usually into the mediastinum that may rarely lead to asphyxia and death. Rare cases with distant metastasis to abdominal lymph nodes, liver or bone have been reported. However, bone marrow involvement has not been previously reported in cases of BI-ALCL.
CASE REPORT
A 58-year-old woman presented with left breast enlargement, firmness, and asymmetry. She had a history of bilateral breast augmentation with textured breast implant Figure 1A) . A needle-core biopsy of the lesion showed a diffuse infiltrate of large cells with vesicular chromatin and prominent nucleoli associated with frequent mitoses. Immunohistochemical studies showed that the neoplastic cells were positive for CD30 (uniform, strong), CD4, CD43, MUM1/IRF4, and BCL-2 and negative for CD3, CD5, CD7, CD10, CD15, CD20, CD56, CD68, CD79a, CD163, anaplastic lymphoma kinase (ALK), epithelial membrane antigen (EMA), BCL-6, PAX-5 and cytokeratin. The neoplasm had a high (90%) Ki-67 (proliferation) index. A diagnosis of BI-ALCL 1,2 was rendered. She underwent explantation of bilateral implants with bilateral capsulectomy ( Figures 1B-D) at the referring institution; the implants and capsule were described as intact. This was followed by delayed bilateral breast reconstruction with deep inferior epigastric artery perforator (DIEP) free flaps 55 days after her initial surgery at which point some tissue was resected from the left breast chest wall. Gross examination of this tissue showed scattered ill-defined masses, 2.3 to 5.2 cm in largest dimension on the luminal side of the capsule that infiltrated into the surrounding soft tissue. Histologic examination revealed BI-ALCL involving the luminal side of the capsule, extending beyond the capsule, and infiltrating into the breast parenchyma and surrounding soft tissue. While sampled margins were uninvolved by lymphoma, complete tumor excision was considered questionable. Approximately 2 months later a repeat mammogram and ultrasound of the chest and left axilla showed an oval, 1. Figures 2B-D) . Due to the extensive systemic involvement, chemotherapy with etoposide, prednisolone, vincristine, cyclophosphamide and hydroxydaunorubicin (EPOCH) was initiated. She completed 5 cycles of EPOCH therapy followed by autologous stem cell transplant and is currently disease free, 14 months following initial diagnosis.
DISCUSSION
BI-ALCL is a rare type of T cell lymphoma. Recent studies estimate the prevalence to be between 1:1000-1:30,000 women with textured breast implants. [3] [4] [5] Over 500 unique cases have been reported (in some form) to date throughout the world. 2, 3, 6, 7 The rates of breast augmentation and implant based breast reconstruction show an increasing trend, therefore, it is expected the number of BI-ALCL will also increase accordingly. 7 This lymphoma is recognized as a provisional entity in the most recent iteration of the World Health Organization classification. 1 present with unilateral or less commonly bilateral breast enlargement as a result of accumulation of an effusion surrounding the breast implant(s). The overall prognosis of patients with BI-ALCL is excellent, particularly when the lymphoma is confined by the fibrous capsule and there is no tumor invasion into the surrounding tissues. 2, 8, 9 Patients with localized disease are typically cured by explantation of the prosthesis and complete excision of the implant capsule in accordance with treatment guidelines established by the National Comprehensive Cancer Network (NCCN). 9, 10 However, approximately 30% of patients present with BI-ALCL beyond the implant capsule, this feature is identified particularly when a tumor mass is formed and is associated with less favorable patient outcomes including shorter overall survival (OS) and event free survival (EFS). 11, 12 Overall, the extent of disease, namely the presence of lymphoma beyond the implant capsule is the strongest predictor of poor patient outcomes. Histologically, most women with BI-ALCL present with disease localized within the effusion or to the fibrous capsule surrounding the implant; 8,13 regional lymph nodes including axillary, supraclavicular, mediastinal, and internal mammary lymph nodes can be involved, but uncommonly, and portend shorter OS. 2, 9, [12] [13] [14] [15] [16] [17] [18] [19] When BI-ALCL involves lymph nodes, it is often indistinguishable from systemic ALK-negative ALCL occurring in lymph nodes and other extranodal sites.
Systemic dissemination by BI-ALCL is exceedingly uncommon. Rare patients with localized bone lesions have been described, 12 but widespread bone and bone marrow involvement has not been previously reported in these patients. Importantly, bone marrow involvement has proven to be an adverse prognostic factor in patients with other forms of ALK-negative ALCL. 20 In summary, the current case represents an undescribed form of BI-ALCL because the patient presented with progressive and disseminated subcutaneous, bone and bone marrow disease, shortly after initial diagnosis. The aggressive clinical presentation of disease in this patient prompted management with systemic chemotherapy and the patient has remained free of disease 14 months after initial diagnosis. Additional follow-up is needed to determine the impact of bone marrow involvement in BI-ALCL. Awareness of these unusual manifestations will aid in establishing a correct diagnosis and facilitate selection of appropriate therapy for patient management.
CONCLUSION
We report the first case of BI-ALCL involving the bone marrow in a patient who presented with aggressive features. Despite initial attempt for complete resection, the disease recurred locally and disseminated to skin and bone marrow within 4 months of initial diagnosis.
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